Ranjit Bindra

Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT.

Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY.

CyVek, Inc. engages in the development of a novel, platform technology for measuring analytes in biological samples. It is a biotechnology company dedicated to the advancement of healthcare by empowering researchers and clinicians with a disruptive technology for performing multi-analyte immunoassays. The firm is a versatile platform that can be quickly and easily configured for diverse applications such as rapid diagnostic tests, multi-sample multi-analyte tests, or routine ELISA-like tests, for use in both research and clinical settings. The company offers an breadth of applications, from life science research to drug discovery, personalized medicine, diagnostics, and point-of-care testing. CyVek was founded by Per J. Hellsund, Rajiv Pandey and Marty Andrew Putnam in 2010 and is headquartered in Wallingford, CT.

Modifi Biosciences is a company based in New Haven, CT that specializes in direct DNA modification to develop novel therapeutics that target tumor-associated DNA repair defects. Modifi Bio has offices and laboratories at the Elm City Bioscience Center, a newly renovated 110,000 square-foot facility within walking distance of Yale that supports emerging New Haven biotechnology companies. The company's goal is to improve the standard of cancer therapy and patient care. The team includes world-renowned scientists, clinicians, and experienced biotech entrepreneurs with expertise in synthetic chemistry, DNA repair, and translational research in oncology. The company was founded by Ranjit S. Bindra and Seth Herzon.

CiDRA Corporate Services, Inc. provides process optimization and enhanced recovery services. Its products include flow measurement, air measurement and grind management. The firm’s services include asset integrity services and chemical management. The company was founded by F. Kevin Didden in 1996 and is headquartered in Wallingford, CT.

Velocity Equity Partners LLC (Velocity Equity Partners) is a venture capital firm founded in 2000 by David Vogel, Sam Foster and Jeff L. Vogel. The firm is headquartered in Boston, Massachusetts.

Part of Illumina, Inc., CyVera Corp. is a company that manufactures an innovative Virtual Cytometer scanning system. The company is based in Wallingford, CT. CyVera was acquired by Semaphore Acquisition Sub, Inc. on April 08, 2005 for $16.66 million.

Cytoveris, Inc. provides health care services. The firm offers assistance cancer surgeons to discern between cancer tissue and healthy tissue in real-time during surgery. The company was founded by Alan Kersey in 1997 and is headquartered in Farmington, CT.

Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021.

Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT.

Part of GSK Plc, GlaxoSmithKline Research & Development Ltd. is a British biopharma company that unites science, technology, and talent to get ahead of disease together. The company was founded in 1965 and is based in Brentford, UK. GSK's work in HIV is carried out entirely through ViiV Healthcare, which GSK majority owns with Pfizer and Shionogi as shareholders. The company is united to do better in various fields, from finance to communications, procurement to HR. GSK provides images and B-roll video for media use and has a privacy notice that applies to any individual who is a current or former registered shareholder of GSK plc.

Oerth Bio LLC is an agricultural biotech company that develops sustainable, environmentally-designed crop and farm solutions to reduce the environmental impact of agrochemical solutions and nourish a growing population with eco-friendly, healthy foods. The company is based in Durham, NC. The company was formed as a joint venture between Arvinas and Bayer, supported by over $55 million in committed funding and operational support from Bayer, and technology and intellectual property from Arvinas. Oerth Bio is reimagining crop protection through a comprehensive, therapeutic approach to crop health using Protac® technology, a targeted biotech solution known for its potential in addressing human disease. The CEO of the company is John W. Dombrosky.

Connecticut United for Research Excellence, Inc. intends to promote public understanding on the benefits of vaccines and medicines that are being offered by bioscience companies. Its members include biomedical research and educational institutions, biotechnology companies, health professionals, and healthcare systems. The company was founded on August 31, 1990 and is headquartered in New Haven, CT.

Shire Regenerative Medicine, Inc. develops and commercializes living cell therapies. It manufactures and markets dermagraft, a bio-engineered skin substitute that assists in restoring damaged tissue and supports the body's natural healing process. The company was founded in 2004 and is headquartered in Westport, CT.

OMRIX Biopharmaceuticals, Inc. specializes in the manufacture and development of biosurgical and passive immunotherapy products. Its product range encompasses hemostatic, surgical, and immunotherapy solutions. The firm offers solutions for bleeding control, surgical operations, and biodefense applications. The company was founded by Robert Taub in 1995 and is headquartered in Somerville, NJ.

Canaan Management, Inc. (Canaan Management) is a venture capital firm founded in 1987 by Eric A. Young. The firm is headquartered in Westport, CT.

Genaissance Pharmaceuticals, Inc. develops and uses genetic information to diagnostic and therapeutic products. The company was founded by Kevin L. Rakin and Gualberto Ruano in 1992 and is headquartered in New Haven, CT.

HighCape Partners Management LLC (HighCape Partners) is a private equity firm founded in 2013 by Kevin Rakin and Matt Zuga. The firm headquartered in Westport, Connecticut..

Cheetah Medical, Inc. develops and markets non-invasive blood monitoring system. The firm offers cheetah sensors, staling SV and cheetah nicom devices. It provides noninvasive hemodynamic monitoring technologies which are designed for use in critical care, operating room and emergency department settings for a wide variety of patient populations. The company was founded by Hanan Keren in 2000 and is headquartered in Newton Center, MA.